Silexion Therapeutics Corp (NASDAQ:SLXN) Sees Large Growth in Short Interest

Posted by Francis Steltz on Aug 26th, 2026

Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) was the target of a significant increase in short interest in August. As of August 14th, there was short interest totaling 119,287 shares, an increase of 460.5% from the July 30th total of 21,284 shares. Currently, 2.2% of the company’s shares are short sold. Based on an average daily volume of 927,154 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of Silexion Therapeutics

A hedge fund recently bought a new stake in Silexion Therapeutics stock. Ancora Advisors LLC bought a new stake in Silexion Therapeutics Corp (NASDAQ:SLXN – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 30,000 shares of the company’s stock, valued at approximately $31,000. Ancora Advisors LLC owned approximately 7.14% of Silexion Therapeutics as of its most recent SEC filing. 10.95% of the stock is owned by institutional investors and hedge funds.

Silexion Therapeutics Trading Down 0.7%

NASDAQ SLXN opened at $0.36 on Wednesday. The company has a market cap of $2.03 million, a P/E ratio of -0.01 and a beta of -0.25. The company has a fifty day simple moving average of $2.00 and a 200 day simple moving average of $7.59. Silexion Therapeutics has a 12-month low of $0.36 and a 12-month high of $80.00.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last released its quarterly earnings data on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($21.20) by $16.03. Sell-side analysts predict that Silexion Therapeutics will post -45.5 EPS for the current year.

Analysts Set New Price Targets

SLXN has been the topic of a number of research analyst reports. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold”.

Read Our Latest Stock Analysis on Silexion Therapeutics

Silexion Therapeutics Company Profile

(Get Free Report)

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.